xPhore™ Platform
Nucleic Acid Delivery (Extrahepatic Tissues)
Platform TechnologyDevelopment & Out-licensing
Key Facts
Indication
Nucleic Acid Delivery (Extrahepatic Tissues)
Phase
Platform Technology
Status
Development & Out-licensing
Company
About Altamira Therapeutics
Altamira Therapeutics is a diversified biotech holding company with a strategic focus on RNA delivery, allergy care, and central nervous system disorders. Its core technology is the xPhore™ platform, a peptide-based nanoparticle system designed for efficient nucleic acid delivery to tissues outside the liver, applicable to siRNA, mRNA, circRNA, and DNA. The company has commercialized Bentrio®, a drug-free nasal spray for allergic rhinitis, while advancing its CNS pipeline through Otolanum AG, positioning itself across both near-term revenue and long-term therapeutic development.
View full company profile